A Phase I, Safety Trial of Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Pancreatic Cancer
- Sponsor
- Baylor Research Institute
- Enrollment
- 7
- Locations
- 1
- Primary Endpoint
- Safety and feasibility of combining the DC vaccine with chemotherapy DC vaccine dose-limiting toxicities will be measured according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
- Status
- Terminated
- Last Updated
- 7 years ago
Overview
Brief Summary
The primary objective is to confirm clinical safety and feasibility of combining the antigen-loaded Dendritic Cell (DC) vaccine with chemotherapy including folinic acid, oxaliplatin, irinotecan and 5-Fluorouracil (5FU) (FOLFIRINOX) and nab-paclitaxel/gemcitabine in patients with pancreatic cancer.
The secondary objectives of this trial are to determine preliminary clinical efficacy based on response rates, overall survival and progression free survival compared with historic control, and surgical conversion rate as defined as percent of locally advanced (unresectable) patients achieving resectability within 6 months of treatment initiation. Also, to identify vaccine immunogenicity by measuring acquired, T cell-mediated immune activating events post-vaccination and to correlate clinical response with acquired immune responses.
Detailed Description
This is a single center, exploratory pilot safety, open label, phase I trial that will evaluate the combination of DC vaccination in 2 groups of patients when combined with chemotherapy including FOLFIRINOX and gemcitabine+nab-paclitaxel in patients with pancreatic cancer. The investigations will accrue 20 evaluable subjects over 20 months with 10 patients in each group. Subjects will be assigned to group 1 or group 2 according to the subject's disease stage. The protocol will be conducted in two stages: The 1st 3 patients will be enrolled to either group to receive DC vaccinations combined with standard chemotherapy. A safety analysis will be performed after the first 3 patients have completed 6 vaccines. If no vaccine dose-limiting toxicity occurs in any of the 3 patients then the study will proceed with stage 2. Stage 2 will include the enrollment of the remaining 17 patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Suspected pancreatic ductal adenocarcinoma (PDAC) prior to diagnosis or histological diagnosis of adenocarcinoma of the pancreas confirmed by pathology.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to
- •Serum Albumin greater than or equal to 2.0 gm/dL
- •Expected survival greater than or equal to 6 months.
- •Adequate hematologic function as defined by
- •Absolute Neutrophil Count (ANC) greater than 1500/mm\^3
- •Platelets greater than or equal to 70,000/mm\^3
- •Hemoglobin greater than 9 g/dL
- •Adequate liver function, as defined by:
- •Serum Total Bilirubin less than or equal to 2 x Upper limit of normal (ULN) mg/dL
Exclusion Criteria
- •History of Organ transplant
- •Other malignancy within 5 years, unless the probability of recurrence of the prior malignancy is \<5% as determined by the principal investigator.
- •Current, active immunosuppressive therapy such as cyclosporine, tacrolimus
- •Subjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics, not toe exceed 10mg Decadron weekly. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning vaccination will be removed from the study.
- •Significant or uncontrolled congestive heart failure, myocardial infarction or significant ventricular arrhythmias within the last 6 months
- •Active infection or antibiotics within 48 hours prior to study enrollment, including unexplained fever
- •Autoimmune disease ( e.g. systemic lupus erythematosis, rheumatoid arthritis). Subjects with remote history of asthma or mild active asthma are eligible.
- •Other severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as:
- •Severe impaired lung functions as defined by spirometry and diffusing capacity of lung for carbon monoxide (DLCO) that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air
- •Uncontrolled diabetes as defined by fasting serum glucose \>250 mg/dL
Outcomes
Primary Outcomes
Safety and feasibility of combining the DC vaccine with chemotherapy DC vaccine dose-limiting toxicities will be measured according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03
Time Frame: 3 Years
Follow up for toxicity will be recorded for the first 30 days following the last DC vaccination and any long-term toxicity will be followed for 3 years after completing study therapy.
Secondary Outcomes
- Progression Free Survival(3 Years)
- Objective Response(3 years)
- Overall Survival(3 years)
- Average of all changes in Quality of Life (QoL) Score(3 Years)